This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MELA Sciences, Inc. [MELA], a medical device company focused on the commercialization of its flagship product, MelaFind®, will visit the NASDAQ MarketSite in Times Square. MelaFind® is the first and only FDA-approved diagnostic tool that is 100% objective and uses multi-spectral light technology to capture and analyze data about irregular moles.
In honor of the occasion,
Joseph V. Gulfo, MD, President and Chief Executive Officer, Claudia Beqaj, Director of Commercialization, Dr. Gary Goldenberg, & Dr. Mark Nestor will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Monday, May 6, 2013 – 9:15 a.m. to 9:30 a.m. ET
Erica Sperling Rpr Marketing Communications (212) 317-1462
Christine Barna (646) 441-5310
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About MELA Sciences, Inc. [MELA]:
MELA Sciences, Inc. is a medical device company focused on the commercialization of its flagship product, MelaFind
®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.
For more information on MELA Sciences, Inc., visit
About NASDAQ OMX Group:
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit
www.nasdaqomx.com . Follow us on Facebook (
http://www.facebook.com/NASDAQ ) and Twitter (
http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)